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Summary
Osteoporosis represents the most common human bone dis-
order with a large medical and economical burden on the
Health Care System. Bisphosphonates are the major drugs
used for the treatment of osteoporosis. Differences in their
chemical structures and pharmacokinetic actions can explain
the different clinical efficacy among these molecules. Rise-
dronate is a potent inhibitor of farnesyl pyrophosphate syn-
thase, but does not bind strongly to mineral; this lower miner-
al binding may enable risedronate to have a wider distribution
in bone. Its antifracture efficacy has been established in sev-
eral randomized phase III controlled studies that showed its
value in the reduction of vertebral, non vertebral and hip frac-
tures. Randomized controlled trials and observational studies
demonstrated risedronate efficacy and safety in different sub-
sets of patients, therefore risedronate is configured, among
oral therapies currently available for osteoporosis, as a drug
of first choice.
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Introduction
Osteoporosis is the most common human bone disorder. It is char-
acterized by low bone mass and microarchitectural deterioration
of bone tissue that leads to enhanced bone fragility and a con-
sequent increase in fracture risk (1).
It places a large medical and economic burden on the Health Care
System and it is expected to become even more common and cost-
ly because of increasing longevity (2). By the year 2050, the in-
cidence in the world of hip fractures, the most serious outcome
of osteoporosis, is expected to increase by 240% in women, and
310% in men (3).
Bisphosphonates, the most used drugs in the treatment of os-
teoporosis, are a very good therapy to reduce the risk of fracture,
and morbidity and mortality associated. They bind to hydroxya-
patite (HAP) in bone and effectively suppress bone resorption by
interfering with osteoclastic activity.
There are important differences among chemical structure of bis-
phosphonates which may explain the different bind to bone min-
eral and some differences in efficacy, speed of onset and offset
action and safety (4).
Chemical features of risedronate
Bisphosphonates contain a chemical backbone of carbon and phos-
phorus in the arrangement -P-C-P-.
Non-nitrogen-containing bisphosphonates (N-BPs) act by incor-
poration into ATP, whereas alkyl aminobisphosphonates act by
farnesyl pyrophosphate synthase (FPPs) inhibition. The hetero-
cyclic N-BPs, as Risedronate, also inhibit the FPPs enzyme and
stabilize its conformation change that magnify their inhibitory po-
tency (4). Risedronate is a unique pyridinil bisphosphonate. 
The R1 and R2 side-chains attached to the carbon atom are re-
sponsible for the range of activity observed among bisphospho-
nates.
Bisphosphonates have in particular two features that influence their
action on bone:
• osteotropism with a strong affinity for hydroxyapatite: the
affinity for the bone and its mineral component affects two key
moments in the pharmacology of the molecules: their uptake
and release (the avidity for bone, the distribution on it and the
cessation of pharmacology); 
• the metabolic action on the skeletal system: the binding affin-
ity of farnesyl pyrophosphate synthase and its inhibition mod-
ulate the function of osteoclasts and therefore their resorptive
potency; recent studies have shown also an action favoring the
function of osteocytes and osteoblasts.
Overall, the different activities of the various bisphosphonates on
the market can be attributed to differences in their affinity towards
the mineral component of bone, and the different inhibitory potency
against the enzyme FPPs.
The order of potency in inhibiting FPPsynthase is zoledronate >
risedronate > ibandronate > alendronate.
The order in the kinetic binding affinity to HAP is clodronate <
etidronate < risedronate < ibandronate < alendronate < pamidronate
< zoledronate (3). 
Risedronate is, therefore, a potent inhibitor of FPPs, but does not
bind strongly to mineral; this lower mineral binding may enable rise-
dronate to have a wider distribution in bone (3).
These data may explain the pharmacological efficacy of risedronate,
such as speed of action, and influence some aspects of molec-
ular pharmacology, such as the half-life in bone tissue that for rise-
dronate is on the order of weeks. The accumulation in bone could
lead to a marked inhibition of the turnover during long-term ther-
apy and a persistence of inhibition after cessation of therapy. Rise-
dronate reduces bone turnover by 50%, but after 12 months of stop-
ping treatment, the bone turnover, assessed with the same pa-
rameters, returns to baseline (5). 
These aspects could influence choices in prolonged and cyclical
treatments and therapies and may also affect the effectiveness
of other concomitant therapy for osteoporosis other than bis-
phosphonates. 
In the recent study OPTAMISE (Clinical Effectiveness of Teri-
paratide After Alendronate or Risedronate therapy in post-
menopausal osteoporotic women) were evaluated women with
post-menopausal osteoporosis previously treated with rise-
dronate or alendronate on the subsequent response to the ad-
ministration of teriparatide.
Patients treated with risedronic acid before treatment with teri-
paratide had a greater anabolic response than those previously
treated with alendronic acid (6). 
Efficacy of Risedronate
Treatment of postmenopausal osteoporotic subjects with rise-
dronate reduces fractures while concomitantly preserving bone
microarchitecture and increasing bone mineral density. 
Risedronate has been available since 2000 and its antifracture ef-
ficacy has been established in several randomized phase III con-
trolled studies.
Vertebral and non vertebral data
Risedronate demonstrated to reduce vertebral and non vertebral
fractures in postmenopausal women with a history of vertebral frac-
ture in two clinical studies, VERT- North America (VERT-NA) (7)
and VERT-Multinational (VERT-MN) (8).
A significant reduction was observed in the risk of new vertebral
fractures by 65% (p < 0.001) and 61% (p = 0.001) after the first
year of treatment with risedronate in VERT-NA and VERT-MN stud-
ies, respectively. This effect was maintained throughout the treat-
ment period (3 years), with significant reduction in the incidence
of new vertebral fractures by 41% (p = 0.003) in VERT-NA and
by 49% in VERT-MN (p < 0.001).
In VERT-NA the significant anti-fracture efficacy was demonstrated
the first year in a population at high risk (i.e. patients with at least
2 or more vertebral fractures): the risk reduction was 74%.
Risedronate has also been shown to significantly reduce the risk
of nonvertebral fractures by 39% (p = 0.02) after 3 years in VERT-
NA.
In postmenopausal women with low bone mineral density (BMD)
with or without prevalent vertebral fractures enrolled in four phase
III studies, risedronate reduced the risk of vertebral osteoporot-
ic fractures by 74% (p = 0.001) (9).
Hip data
Hip fractures are the most serious outcome of osteoporosis be-
cause of the associated morbidity, mortality, and costs. The Hip
Intervention Program on 9.331 patients was the first and largest
clinical study on a bisphosphonate having as primary objective to
assess its efficacy on femoral fractures (10). The results demon-
strated that treatment with risedronate significantly reduces the
risk of hip fractures in osteoporotic women.
In the general population, risedronate reduced the risk of fractures
by 30% (p = 0.02).
The risk reduction was 41% versus placebo over 3 years in women
with low bone mineral density at the femoral neck and 60% ver-
sus placebo in women with low bone mineral density at the femoral
neck and at least one prevalent vertebral fracture.
Fast action
The speed of action is a feature of great importance for two rea-
sons:
• the previous fragility fracture is the most important risk factor
of new fractures and the risk is highest within the first year af-
ter fracture (11) 
• the mean time of adherence to therapy is about 8 months (12),
so the faster a drug is, the more the patient will actually bene-
fit from its therapeutic efficacy.
Risedronate is the only bisphosphonate that has been shown to
reduce significantly the risk of both vertebral and non vertebral frac-
tures in 6 months of therapy (13, 14).
The increased speed of action was also demonstrated in patients
with corticosteroids induced osteoporosis, in which risedronate re-
duced by 70% (p < 0.01) the risk of vertebral fractures at one year
in both genders (15).
Long term efficacy
Osteoporosis is a chronic disease, therefore needs a medium-long
term therapy.
In order to determine the effects of 5 years of risedronate treat-
ment, Sorensen et al. performed an extension of a 3-year, place-
bo-controlled study in 265 post-menopausal women, with at least
two prevalent vertebral fractures for an additional 2 years: after
this period risedronate demonstrated its efficacy in reducing the
risk of new vertebral fractures by 59% (incidence of vertebral frac-
tures in the risedronate group 13.8%, incidence in the placebo group
28.2%: p = 0.01) (16).
Similar levels of risk reduction were maintained in a further ex-
tension of two years of the original study (total duration of 7 years)
(17).
Observational studies
Randomized controlled trials (RCTs) are the gold standard for de-
termining drug efficacy and safety. RCTs are designed to mini-
mize internal bias and to maximize treatment effect. However, their
design creates shortfalls with regards to external validity of the out-
comes.
Many patients with osteoporosis, in fact, can not be included in
standard RCTs because of co-morbidities and prior therapies.
REAL retrospective study carried out on 34000 patients showed
rapid effectiveness of risedronate (18). After a year of therapy with
risedronate 35 mg/week the incidence of hip fractures (-43%, p
= 0.01) and nonvertebral fractures (- 18%: p = 0.03) is lower than
in patients treated with alendronate 70 mg / week.
In a recent real life study (CLEAR study, Longitudinal Change in
Clinical Fracture Incidence After Initiation of Bisphosphonates) (19),
administrative database were used to follow three cohorts of women
aged 65 and older (total n = 210,144) after starting therapy either
on alendronate, risedronate, or ibandronate in the USA between
market introduction and 2006. Within each cohort, the baseline
incidence of clinical fractures at the hip, vertebral, and nonverte-
bral sites was defined by the initial 3-month period after starting
therapy. Relative to these baselines, the authors then compared
the fracture incidence during the subsequent 12 months on ther-
apy. Relative to the baseline incidence, fracture incidence was sig-
nificantly lower in the subsequent 12 months in both cohorts of
alendronate (18% lower at hip, 28% at nonvertebral sites, and 57%
at vertebral sites) and risedronate (27% lower at hip, 21% at non-
vertebral sites, and 54% at vertebral sites). In the ibandronate co-
hort, the fracture incidence was lower (31%) only at vertebral sites.
The reductions observed in fracture incidence over time within each
cohort suggest that the effectiveness of each bisphosphonate in
clinical practice has been consistent with their efficacies demon-
strated in randomized controlled trials.
Risedronate efficacy in different subsets of patients
Risedronate is also indicated for osteoporosis in men. In 316 men
with primary or secondary osteoporosis, risedronate 5 mg/day sig-
nificantly reduced by 60% the incidence of new vertebral fractures
after one year of therapy (incidence of vertebral fractures in the
risedronate group 5.1%, incidence in the placebo group 12.6% p
= 0.028) (24) and significantly reduced by 61% the incidence of
new vertebral fractures after two years of therapy (incidence of
vertebral fractures in the risedronate group 9.2%, incidence in the
placebo group 23.6%, p = 0.0026) (25). Risedronate significant-
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ly reduced by 45% the incidence of new nonvertebral fractures af-
ter two years of therapy (incidence of nonvertebral fractures in the
group risedronate 11.8%, incidence in the placebo group 22.3%,
p = 0.032) (25).
In a study on 284 men with primary osteoporosis it was shown an
increase of BMD at the lumbar spine, statistically significant (4.5%,
p < 0.0001) in patients treated with risedronate 35 mg once a week
compared to placebo. This effect was already significant after the
first 6 months of treatment (2.6%, p < 0.0001) (26). 
In another study, risedronate demonstrated to increase BMD and
to reduce hip fractures in elderly poststroke men (27).
There is a high incidence of hip fractures in patients after hemi-
plegic stroke, and bone mineral density is decreased on the hemi-
plegic side in these patients, correlating with the immobilization-
induced bone resorption, the degree of paralysis, and hypovita-
minosis D; the purpose of this study was to evaluate the effec-
tiveness of risedronate on osteoporosis and the risk of hip frac-
tures in men 65 years or older after stroke. Risedronate signifi-
cantly reduced by 81% the incidence of hip fracture (95% confi-
dence interval, 0.04-0.89). 
Risedronate has been shown to reduce proximal bone resorption
around the femoral stem in patients with total hip arthroplasty (eval-
uation of bone mineral density in the seven Gruen zones and mark-
ers of bone turnover) (28, 29).
Tolerability
In general, there is a good safety profile for bisphosphonates. 
To review the frequency of upper gastrointestinal (GI) events with
risedronate, Taggart et al. pooled nine multicenter, randomized
placebo controlled studies on risedronate (30).
Sixty percent of patients had a history of GI tract disease, 38.7%
had active GI tract disease, and 20.5% used antisecretory drugs
during the studies. Sixty-three percent used aspirin and/or non-
steroidal anti-inflammatory drugs during the studies. Upper GI ad-
verse events were reported by 29.6% of patients in the placebo
arm compared with 29.8% in the risedronate arm. In addition, en-
doscopy performed in 349 patients demonstrated no significant
difference among the two groups. 
Renal side effects were also studied, given that bisphosphonates
are cleared by the kidney. Miller et al. pooled the results of nine
clinical trials, revealing no significant differences in incidence of
renal toxicity between daily risedronate and placebo with base-
line renal function being the same between the two groups. Rise-
dronate was found to have no effect on specific renal function or
general adverse events across mild, moderate, and severe age-
related renal dysfunction (31).
Conclusions
Based on the RCTs and observational studies, for the proven ef-
ficacy on all skeletal sites and the high safety profile, risedronate
is configured, among oral therapies currently available for os-
teoporosis, as a therapy of first choice.
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